�Oncolytics Biotech Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that the U.S.
National Cancer Institute (NCI), part of the National Institutes of Health,
has started enrollment in a Phase 2 clinical trial for patients with
metastatic melanoma using systemic presidency of REOLYSIN(R),
Oncolytics' proprietorship formulation of the human reovirus. The trial is
being carried out by the Mayo Phase 2 Consortium under the NCI's Clinical
Trials Agreement with Oncolytics, patch Oncolytics will provide clinical
supplies of REOLYSIN(R). The Principal Investigator is Dr. Evanthia Galanis
of the Mayo Clinic Cancer Center.
The basal objectives of the survey are to assess the antitumour
effects of REOLYSIN(R) in patients with metastatic malignant malignant melanoma, as
well as the safety profile of REOLYSIN(R). Secondary objectives include
assessment of patterned advance free survival of the fittest and boilersuit survival.
Patients will pick up systemic administration of REOLYSIN(R) at a dose
of 3x10(10) TCID(50) per day on days 15 of each 28 day cycle, and patients
may receive up to 12 cycles of treatment. The trial is expected to enroll
up to 47 patients with metastatic malignant melanoma.
Approximately 60,000 masses are diagnosed with malignant melanoma in the U.S.
every year.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
ontogenesis of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical programme includes a variety of Phase I/II and Phase II
human trials victimisation REOLYSIN(R), its proprietary preparation of the human
reovirus, alone and in combination with radiation or chemotherapy. For
further information about Oncolytics, please visit
hTTP://www.oncolyticsbiotech.com
This press release contains advanced statements, inside the
significance of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's expectations related to
the U.S. NCI Phase 2 systemic administration clinical trial for patients
with metastatic malignant melanoma, and the Company's notion as to the potentiality of
REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to disagree
materially from those in the innovative statements. Such risks and
uncertainties include, among others, the availableness of funds and
resources to go after research and development projects, the efficacy of
REOLYSIN(R) as a cancer discussion, the tolerability of REOLYSIN(R) outside
a controlled quiz, the success and seasonable completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN(R), uncertainties related to the enquiry and development of
pharmaceuticals and uncertainties related to the regulative process.
Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional entropy on
risks and uncertainties relating to the forward looking statements.
Investors ar cautioned against placing inordinate reliance on forward-looking
statements. The Company does non undertake to update these forward-looking
statements.
Oncolytics Biotech Inc.
http://www.oncolyticsbiotech.com
More info
